Does Hopeful Vaccine Data Make Ocugen a Buy?
Ocugen (NASDAQ: OCGN) officially joined the coronavirus vaccine race last month when it partnered with Indian company Bharat Biotech -- which already had a vaccine candidate in phase 3 studies in its home country. The two agreed to co-commercialize an eventual vaccine in the U.S. Ocugen's shares have soared about 330% since the start of February on optimism about this potential revenue source. This week, Bharat reported favorable data in its first interim trial report.
